Compare CORT & CRDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CORT | CRDO |
|---|---|---|
| Founded | 1998 | 2008 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 50.7B |
| IPO Year | 2001 | 2022 |
| Metric | CORT | CRDO |
|---|---|---|
| Price | $114.03 | $209.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 19 |
| Target Price | $141.00 | ★ $280.10 |
| AVG Volume (30 Days) | 815.6K | ★ 8.3M |
| Earning Date | 11-03-2026 | 09-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 765.52 |
| EPS | 0.09 | ★ 0.67 |
| Revenue | $761,407,000.00 | ★ $1,335,116,000.00 |
| Revenue This Year | $50.53 | $87.36 |
| Revenue Next Year | $48.75 | $54.96 |
| P/E Ratio | $1,275.83 | ★ $288.95 |
| Revenue Growth | 12.79 | ★ 205.68 |
| 52 Week Low | $28.66 | $86.49 |
| 52 Week High | $126.38 | $308.67 |
| Indicator | CORT | CRDO |
|---|---|---|
| Relative Strength Index (RSI) | 51.85 | 52.72 |
| Support Level | $108.33 | $181.43 |
| Resistance Level | $124.30 | $210.97 |
| Average True Range (ATR) | 5.17 | 8.98 |
| MACD | -0.14 | 4.72 |
| Stochastic Oscillator | 53.19 | 76.40 |
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
Credo Technology Group Holding Ltd provides connectivity solutions for AI-driven applications, cloud computing, and hyperscale networks. Its high-speed copper and optical interconnect products support data infrastructure demands. The Company's product portfolio includes ZeroFlap (ZF) Active Electrical Cables (AECs), ZF optical transceivers, OmniConnect memory solutions, and retimers and DSPs for optical and copper Ethernet and PCIe, leveraging the PILOT diagnostic and analytics software platform. Its products are based on Serializer/Deserializer (SerDes) and Digital Signal Processor (DSP) technologies and include integrated circuits (ICs), Active Electrical Cables (AECs), SerDes Chiplets, and SerDes IP licensing solutions. The United States generates the maximum revenue.